Bremelanotide

Drug Profile

Bremelanotide

Alternative Names: PT-141; RekyndaTM

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arizona
  • Developer Palatin Technologies; Simons Foundations
  • Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Female sexual dysfunction
  • Phase II Cognition disorders
  • No development reported Erectile dysfunction
  • Discontinued Haemorrhagic shock; Vascular disorders

Most Recent Events

  • 06 Sep 2017 Bremelanotide licensed to Shanghai Fosun Pharmaceutical in China, Taiwan, Hong Kong and Macau for Female sexual dysfunction
  • 04 Aug 2017 Drug interactions data released by AMAG Pharmaceuticals
  • 11 Jul 2017 Palatin Technologies has patent protection for bremelanotide for methods of treating female sexual dysfunction and hypoactive sexual desire disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top